Rasio utang jangka cendhak marang ekuitas: Cara Therapeutics, Inc. (CARA)

This daily price chart for Cara Therapeutics, Inc. (CARA) reflects the asset's dynamics, with its indicator fixed at 0.02. Cara Therapeutics, Inc. (CARA) is developing a comprehensive environment for the therapy of renal pruritus by integrating its treatments into the practice of dialysis clinics. The business relies on the creation of unique selective kappa-receptor agonists, actively investing in the study of small molecules. The stability of its neurology expert staff is guaranteed by robust intellectual property protection.

Driven by strong pricing power in licensing its unique peptide, Corsuva, Cara Therapeutics, Inc. (CARA) effectively manages liquidity; consequently, the short-term debt-to-equity ratio, which measures the proportion of liabilities with a term exceeding one year relative to equity, serves as an indicator of debt sustainability, allowing investors to distinguish market noise from actual credit crisis risks through the price action on this chart.